Eterna Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing advanced therapies using Messenger RNA (mRNA) cell engineering technology. The Company is engaged in developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its product pipeline is based on patented foundational mRNA cell engineering technology and offers multiple clinical applications with future sub-licensing and partnering opportunities. It formulates mRNA using lipid nanoparticle (LNP) technology. The ToRNAdo delivery system surrounds and protects the mRNA cargo, enabling delivery into human cells. The Company has licensed a portfolio of over 100 patents covering key cell engineering technologies, including therapeutic gene editing in clinical development. It has multiple cell and gene-editing therapies in preclinical development for various indications.
No insider trading activity.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.